Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 12—December 2022

Orthopoxvirus Seroprevalence and Infection Susceptibility in France, Bolivia, Laos, and Mali

Léa LucianiComments to Author , Nathanaël Lapidus, Abdennour Amroun, Alessandra Falchi, Chanthala Souksakhone, Mayfong Mayxay, Audrey Dubot-Pérès, Paola Mariela Saba Villarroel, Issa Diarra, Ousmane Koita, Pierre Gallian, and Xavier de Lamballerie
Author affiliations: Aix-Marseille Université-IRD 190-Inserm 1207, Marseille, France (L. Luciani, A. Amroun, A. Dubot-Pérès, P.M. Saba Villarroel, I. Diarra, P. Gallian, X. de Lamballerie); Sorbonne Université, Inserm, Saint-Antoine Hospital, Paris, France (N. Lapidus); Université de Corse Pascal Paoli, Corte, France (A. Falchi); Lao Red Cross, Vientiane, Laos (C. Souksakhone); Ministry of Health, Vientiane (M. Mayxay); University of Health Sciences, Vientiane (M. Mayxay); Mahosot Hospital, Vientiane (M. Mayxay, A. Dubot Pérès); University of Oxford, Oxford, UK (M. Mayxay, A. Dubot Pérès); University of Sciences, Bamako, Mali (I. Diarra, O. Koita); Établissement Français du Sang, La Plaine Saint Denis, France (P. Gallian)

Main Article

Table 2

Cross-reactivity between antibodies against vaccinia and cowpox viruses in serum samples of study participants from France in study of orthopoxvirus seroprevalence and infection susceptibility in France, Bolivia, Laos, and Mali*

Antibody titers, vaccinia virus Antibody titer, cowpox virus
10 20 40 80 160
10 3,443 (77.44) 407 (9.15) 4 (0.09) 2 (0.04) 1 (0.02)
20 234 (5.26) 85 (1.91) 12 (0.27) 5 (0.11) 0
40 7 (0.16) 77 (1.73) 62 (1.39) 12 (0.27) 3 (0.07)
80 0 4 (0.09) 31 (0.70) 21 (0.47) 3 (0.07)
160 0 1 (0.02) 0 2 (0.04) 2 (0.04)

*Values are no. (%). Percentages were calculated according to 4,448 participants in France who had serum samples tested for antibodies against both vaccinia and cowpox viruses by using the seroneutralization assay.

Main Article

Page created: October 14, 2022
Page updated: November 21, 2022
Page reviewed: November 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.